Eurobio-Scientific SA (FR:ALERS)
:ALERS
Top Page
Eurobio-Scientific SA
(ALERS)
Select Model
Select Model
Rating:42Neutral
Price Target:
€24.00
▼(-0.62% Downside)
Action:ReiteratedDate:10/10/25
The overall score is low, primarily driven by bearish technical indicators and a very high valuation. The stock is trading below all key moving averages, suggesting a negative trend, and its P/E ratio of 106.36 indicates it is significantly overvalued relative to earnings. The lack of available financial data prevents a more comprehensive assessment.
Positive Factors
Revenue Growth
Strong revenue growth indicates robust demand for Eurobio-Scientific's diagnostic products, supporting long-term business expansion and market penetration.
Negative Factors
Profitability Margins
Declining operational efficiency, as indicated by reduced EBIT and EBITDA margins, could hinder Eurobio-Scientific's ability to maintain profitability, impacting long-term financial health.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Strong revenue growth indicates robust demand for Eurobio-Scientific's diagnostic products, supporting long-term business expansion and market penetration.
Read all positive factors
Eurobio-Scientific SA (ALERS) vs. iShares MSCI France ETF (EWQ)
Market Cap
€227.12M
Dividend YieldN/A
Average Volume (3M)968.00
Price to Earnings (P/E)27.0
Beta (1Y)-0.26
Revenue Growth12.47%
EPS Growth-65.87%
CountryFR
Employees329
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.23
Shares Outstanding10,248,871
10 Day Avg. Volume1,061
30 Day Avg. Volume968
Financial Highlights & Ratios
PEG Ratio-6.95
Price to Book (P/B)1.45
Price to Sales (P/S)1.67
P/FCF Ratio19.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.13
Revenue Forecast (FY)€175.90M
Eurobio-Scientific SA Business Overview & Revenue Model
Company Description
Eurobio Scientific Société anonyme designs, develops, and commercializes specialty diagnostic products in the areas of transplantation, infectious diseases, life-science, and cancer. The company offers Tetanus Quick Stick, a test that is used in e...
How the Company Makes Money
Eurobio-Scientific SA generates revenue primarily through the sale of its diagnostic products, including reagents, kits, and associated laboratory equipment. The company has established key revenue streams from both direct sales to healthcare prov...
Eurobio-Scientific SA Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 162.83M | 154.95M | 130.65M | 152.61M | 184.71M | 188.86M |
| Gross Profit | 74.73M | 71.95M | 57.49M | 65.04M | 97.44M | 105.61M |
| EBITDA | 18.74M | 20.40M | 24.55M | 40.49M | 79.63M | 88.57M |
| Net Income | 2.40M | 4.00M | 4.83M | 24.94M | 60.54M | 73.48M |
Balance Sheet | ||||||
| Total Assets | 259.11M | 257.17M | 316.33M | 330.42M | 209.22M | 172.30M |
| Cash, Cash Equivalents and Short-Term Investments | 26.86M | 23.07M | 89.03M | 85.94M | 102.39M | 65.56M |
| Total Debt | 20.36M | 34.05M | 100.66M | 113.60M | 15.68M | 29.70M |
| Total Liabilities | 78.26M | 78.31M | 141.16M | 157.75M | 49.00M | 64.45M |
| Stockholders Equity | 180.85M | 178.85M | 175.17M | 172.34M | 159.91M | 107.11M |
Cash Flow | ||||||
| Free Cash Flow | 7.46M | 13.45M | 22.71M | 39.01M | 63.61M | 52.02M |
| Operating Cash Flow | 8.99M | 16.70M | 26.77M | 41.85M | 65.46M | 54.31M |
| Investing Cash Flow | -9.30M | -10.74M | -318.00K | -141.76M | -5.47M | -3.98M |
| Financing Cash Flow | -63.34M | -72.09M | -23.50M | 82.31M | -23.75M | 7.67M |
Eurobio-Scientific SA Technical Analysis
Positive
24.15
Price Trends
22.98
Negative
23.63
Negative
24.36
Negative
Market Momentum
-0.30
Negative
53.31
Neutral
71.79
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALERS, the sentiment is Positive. The current price of 24.15 is above the 20-day moving average (MA) of 22.07, above the 50-day MA of 22.98, and below the 200-day MA of 24.36, indicating a neutral trend. The MACD of -0.30 indicates Negative momentum. The RSI at 53.31 is Neutral, neither overbought nor oversold. The STOCH value of 71.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ALERS.
Eurobio-Scientific SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | €22.74M | -5.20 | -17.18% | ― | 138.92% | 11.14% | |
47 Neutral | €167.05M | -0.80 | 59.08% | ― | 6.75% | 15.48% | |
44 Neutral | €27.29M | -2.19 | -14.58% | ― | 5.10% | 17.34% | |
44 Neutral | €123.71M | -1.02 | ― | ― | -9.32% | 56.88% | |
42 Neutral | €227.12M | 26.96 | 1.32% | ― | 12.47% | -65.87% |
* Healthcare Sector Average
FR:ALERS
Eurobio-Scientific SA
22.70
-0.80
-3.40%
FR:ALNOV
Novacyt
0.38
-0.11
-22.47%
FR:ALDMS
Diagnostic Medical Systems
1.33
0.42
47.22%
FR:ALIKO
Ikonisys SA
1.44
0.03
2.13%
FR:ALMDT
Median Technologies
4.44
1.84
70.57%
FR:EAPI
Euroapi SA
1.30
-1.00
-43.57%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.